DelveInsight’s “Cushing’s Syndrome Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Cushing’s Syndrome pipeline landscapes. It comprises Cushing’s Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cushing’s Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cushing’s Syndrome pipeline products.
Some of the key takeaways of the Cushing’s Syndrome Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, etc., are developing therapies for the treatment of Cushing’s Syndrome.
-
Emerging therapies such as Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, are expected to have a significant impact on the Cushing’s Syndrome market in the coming years.
-
Osilodrostat is an orally administered steroidogenesis inhibitor of 11Beta-hydroxylase, an enzyme that catalyses the final step of cortisol synthesis in the adrenal cortex. This molecule is currently in Phase III of clinical development.
Get an overview of pipeline landscape @ Cushing’s Syndrome Clinical Trials Analysis
Cushing’s syndrome (CS) is a rare problem caused when the adrenal gland(s) makes too much of a hormone called cortisol. CS is most often due to a tumour or mass found in the pituitary gland, but can also be caused by tumours in the adrenal glands themselves.
Cushing’s Syndrome Emerging Drugs
-
Osilodrostat by Recordati
-
Relacorilant by Corcept Therapeutics
-
ATR-101 by Millendo Therapeutics
-
Levoketoconazole by Cortendo
-
ST-002 by SteroTherapeutics
For further information, refer to the detailed report @ Cushing’s Syndrome Pipeline Therapeutics
Scope of Cushing’s Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, and others.
-
Pipeline Therapies: Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, and others.
Table of Contents
|
1 |
Cushing’s Syndrome Report Introduction |
|
2 |
Cushing’s Syndrome Executive Summary |
|
3 |
Cushing’s Syndrome Overview |
|
4 |
Cushing’s Syndrome- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Cushing’s Syndrome Pipeline Therapeutics |
|
6 |
Cushing’s Syndrome Late Stage Products (Phase II/III) |
|
7 |
Cushing’s Syndrome Mid Stage Products (Phase II) |
|
8 |
Cushing’s Syndrome Early Stage Products (Phase I) |
|
9 |
Cushing’s Syndrome Preclinical Stage Products |
|
10 |
Cushing’s Syndrome Therapeutic Assessment |
|
11 |
Cushing’s Syndrome Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Cushing’s Syndrome Key Companies |
|
14 |
Cushing’s Syndrome Key Products |
|
15 |
Cushing’s Syndrome Unmet Needs |
|
16 |
Cushing’s Syndrome Market Drivers and Barriers |
|
17 |
Cushing’s Syndrome Future Perspectives and Conclusion |
|
18 |
Cushing’s Syndrome Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/